Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,973 questions · 3,072 findings · 410 reviews · Headline outcomes only

No studies found 559 · 18.2%GRADE not reported 143 · 4.7%Very low 654 · 21.3%Low 833 · 27.1%Moderate 683 · 22.2%High 200 · 6.5%

Aclidinium bromide vs placebo

Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease

Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality · patients with managing pulmonary tuberculosis

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Intervention not reported

Sputum Conversion by 2 months · patients with managing pulmonary tuberculosis

The intervention may leads to higher sputum Conversion by 2 months (low certainty).

1 finding from 1 review

Intervention not reported

Sputum conversion at 6 months · patients with managing pulmonary tuberculosis

The intervention showed no clear difference in sputum conversion at 6 months (moderate certainty).

1 finding from 1 review

Intervention not reported

Clinical Improvement at 1 month · patients with managing pulmonary tuberculosis

It is very uncertain whether the intervention changes clinical Improvement at 1 month (very low certainty).

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events at study endpoint · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).

2 findings from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—400/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Mometasone/formoterol (MF/F) vs placebo

Adverse events—serious—200/103 Duration of six months · patients with chronic obstructive pulmonary disease

Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).

1 finding from 1 review

Intervention not reported

Survival · patients with unresectable periampullary carcinoma

It is very uncertain whether the intervention changes survival (very low certainty).

1 finding from 1 review

Intervention not reported

Gastric outlet obstruction Clinical symptoms of vomiting with confirmation of the gastric outlet obstruction by radiological or endoscopic investigations · patients with unresectable periampullary carcinoma

It is very uncertain whether the intervention changes gastric outlet obstruction Clinical symptoms of vomiting with… (very low certainty).

1 finding from 1 review

Long‐acting beta2‐agonists vs placebo

Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease

Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).

1 finding from 1 review